Key facts
- It has raised $1.4M; the latest was Later Stage VC ($1.4M) in Dec 2024.
- Notable investors include Huayi Capital, Guangrun Fund.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Yangrui Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Yangrui Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yangrui Bio
Developer of clinical diagnostic technology designed for Biotechnology. The company's products mainly focus on rapid and efficient clinical diagnostic technology development and transformation, and it developed several original technologies in NGS, isothermal amplification, and other fields, providing customers with reliable and innovative products.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2019
- Employees
- 2
- Ownership
- Privately Held (backing)
Yangrui Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yangrui Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yangrui Bio in its N-PORT filings yet. We sweep new filings monthly.